Patients in the ivonescimab group demonstrated a significantly greater progression-free survival than those in the ...

Opdivo (nivolumab) is a brand-name IV infusion prescribed for non-small cell lung cancer (NSCLC) in some situations. This article covers topics such as side effects, dosage, and how Opdivo works.

Q1 2025 Management View Executive Chairman Bill Doyle highlighted the company’s transition to a multi-indication oncology company, emphasizing the regulatory and commercial advancements. He announced ...

The global non-small cell lung cancer market is on track for exceptional growth, driven by increasing demand for innovative treatment solutions. According to recent market projections, the market ...

The trial previously reported a 71% objective response rate (ORR) – indicating tumor shrinkage – in 75 patients from the first cohort, but newly presented data include a median duration of response ...

“Optune Lua is an innovative and urgently needed new approach for treating metastatic non-small cell lung cancer,” said Joachim Aerts, M.D., a LUNAR investigator and Professor of Pulmonary ...

Jobevne is approved for multiple cancer types, including colorectal, non-small cell lung, and glioblastoma, among others. It functions as a VEGF inhibitor, preventing angiogenesis and restricting ...

Key exclusion criteria included a history of severe immune-related adverse events from prior immune checkpoint inhibitor use, untreated or symptomatic central nervous system metastases, and a history ...